Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

NCT01685021 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: MOR00208 (formerly Xmab5574)

Sponsor

MorphoSys AG